CompletedNot Applicable

Feasibility of Monitoring Health Data in Pediatric Patients Undergoing Chemotherapy

Switzerland20 participantsStarted 2019-11-29

Plain-language summary

In this pilot study the feasibility of continous monitoring of health data with a small, on-skin wearable device (the Everion®, by Biovotion, Zurich) in pediatric patients under chemotherapy for cancer, is studied. Feasibility is assessed by the number of patients wearing the device on seven consecutive days for at least 18h/day, what will be measured by monitored heart rate. Study duration for each participant is 14 days.

Who can participate

Age range1 Month – 17 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Chemotherapy treatment because of any malignancy, expected to last ≥1 months at time of recruitment for myelosuppressive therapy or at least one cycle of myeloablative therapy. * Age 1 month to \<18 years at time of recruitment * Written informed consent from patients and/or parents Exclusion Criteria: * Local skin diseases prohibiting wearing of the device. * Denied written informed consent from patients and/or parent

What they're measuring

Feasibility of Continous Monitoring of Heart Rate With the Wearable Device (WD)

Timeframe: 14 days

Trial details

NCT IDNCT04134429

SponsorInsel Gruppe AG, University Hospital Bern

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2020-01-13

Results submitted2021-04-12

View on ClinicalTrials.gov More Pediatric Cancer trials